| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Mullerian Hormone | 8 | 2025 | 42 | 4.690 |
Why?
|
| Ovary | 10 | 2021 | 354 | 3.720 |
Why?
|
| Ovulation Induction | 7 | 2024 | 38 | 2.670 |
Why?
|
| Uterus | 8 | 2024 | 542 | 2.320 |
Why?
|
| Endometrium | 8 | 2025 | 280 | 2.270 |
Why?
|
| Ultrasonography | 11 | 2025 | 972 | 2.100 |
Why?
|
| Fertilization in Vitro | 6 | 2025 | 143 | 2.000 |
Why?
|
| Pregnancy Trimester, First | 7 | 2024 | 119 | 1.970 |
Why?
|
| Gonadotropin-Releasing Hormone | 7 | 2013 | 70 | 1.890 |
Why?
|
| Urogenital Abnormalities | 4 | 2021 | 160 | 1.830 |
Why?
|
| Ultrasonography, Prenatal | 12 | 2024 | 998 | 1.680 |
Why?
|
| Ovarian Follicle | 3 | 2025 | 121 | 1.610 |
Why?
|
| Fertility Preservation | 4 | 2025 | 61 | 1.600 |
Why?
|
| Abortion, Spontaneous | 4 | 2021 | 82 | 1.510 |
Why?
|
| Granulosa Cells | 2 | 2025 | 140 | 1.450 |
Why?
|
| Hysteroscopy | 4 | 2021 | 14 | 1.420 |
Why?
|
| Embryo Transfer | 4 | 2025 | 44 | 1.390 |
Why?
|
| Polyps | 2 | 2021 | 40 | 1.350 |
Why?
|
| Pregnancy | 40 | 2025 | 7492 | 1.290 |
Why?
|
| Yolk Sac | 2 | 2020 | 13 | 1.250 |
Why?
|
| Polycystic Ovary Syndrome | 4 | 2020 | 63 | 1.220 |
Why?
|
| Infertility, Female | 5 | 2015 | 147 | 1.120 |
Why?
|
| Pregnancy Outcome | 10 | 2025 | 627 | 1.110 |
Why?
|
| Cyclophosphamide | 4 | 2014 | 435 | 1.100 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2013 | 68 | 1.060 |
Why?
|
| Oocytes | 5 | 2023 | 272 | 0.990 |
Why?
|
| Female | 64 | 2025 | 70509 | 0.880 |
Why?
|
| Preimplantation Diagnosis | 1 | 2025 | 25 | 0.880 |
Why?
|
| Ultrasonography, Doppler | 8 | 2006 | 185 | 0.870 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2014 | 99 | 0.860 |
Why?
|
| Sexual Maturation | 2 | 2013 | 45 | 0.810 |
Why?
|
| Fertility Agents, Female | 3 | 2017 | 7 | 0.810 |
Why?
|
| Fetus | 5 | 2018 | 584 | 0.800 |
Why?
|
| Embryo Implantation | 1 | 2025 | 215 | 0.780 |
Why?
|
| Follicle Stimulating Hormone | 4 | 2018 | 182 | 0.750 |
Why?
|
| Placenta Accreta | 1 | 2025 | 175 | 0.730 |
Why?
|
| Cryopreservation | 4 | 2025 | 77 | 0.710 |
Why?
|
| Estradiol | 4 | 2018 | 476 | 0.710 |
Why?
|
| Sodium Chloride | 1 | 2021 | 90 | 0.700 |
Why?
|
| Reproduction | 2 | 2013 | 214 | 0.700 |
Why?
|
| Receptors, Peptide | 2 | 2020 | 56 | 0.690 |
Why?
|
| Down-Regulation | 4 | 2025 | 654 | 0.690 |
Why?
|
| Insulins | 1 | 2021 | 18 | 0.690 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2020 | 105 | 0.670 |
Why?
|
| Genes, BRCA2 | 1 | 2020 | 48 | 0.660 |
Why?
|
| Pregnancy Complications | 5 | 2020 | 539 | 0.660 |
Why?
|
| Genes, BRCA1 | 1 | 2020 | 59 | 0.650 |
Why?
|
| Gestational Sac | 1 | 2020 | 2 | 0.640 |
Why?
|
| Fallopian Tubes | 1 | 2020 | 67 | 0.630 |
Why?
|
| RNA, Messenger | 4 | 2020 | 2556 | 0.620 |
Why?
|
| Sperm Injections, Intracytoplasmic | 3 | 2008 | 50 | 0.620 |
Why?
|
| Adult | 29 | 2025 | 31202 | 0.610 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 1312 | 0.610 |
Why?
|
| Humans | 63 | 2025 | 130574 | 0.600 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 21 | 0.590 |
Why?
|
| Primary Ovarian Insufficiency | 3 | 2014 | 51 | 0.590 |
Why?
|
| Pilot Projects | 5 | 2021 | 1456 | 0.560 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 1791 | 0.560 |
Why?
|
| Genetic Testing | 1 | 2025 | 1087 | 0.550 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2017 | 379 | 0.550 |
Why?
|
| Apoptosis | 3 | 2020 | 1849 | 0.550 |
Why?
|
| Receptors, Pituitary Hormone | 1 | 2017 | 2 | 0.550 |
Why?
|
| Hormone Antagonists | 2 | 2008 | 43 | 0.550 |
Why?
|
| Blood Flow Velocity | 9 | 2006 | 423 | 0.540 |
Why?
|
| Heterografts | 1 | 2018 | 193 | 0.540 |
Why?
|
| Logistic Models | 2 | 2020 | 1814 | 0.530 |
Why?
|
| Receptors, FSH | 3 | 2025 | 19 | 0.520 |
Why?
|
| Erythroblastosis, Fetal | 5 | 2003 | 27 | 0.520 |
Why?
|
| Inhibins | 3 | 2025 | 85 | 0.510 |
Why?
|
| Mullerian Ducts | 1 | 2017 | 45 | 0.500 |
Why?
|
| Pregnancy, Multiple | 2 | 2019 | 39 | 0.490 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 2343 | 0.480 |
Why?
|
| Neoplasms | 3 | 2025 | 2951 | 0.470 |
Why?
|
| Middle Cerebral Artery | 5 | 2003 | 115 | 0.460 |
Why?
|
| Placenta | 1 | 2019 | 513 | 0.430 |
Why?
|
| Pregnancy Rate | 3 | 2025 | 34 | 0.430 |
Why?
|
| Goserelin | 1 | 2014 | 4 | 0.420 |
Why?
|
| Receptors, Progesterone | 3 | 2021 | 675 | 0.420 |
Why?
|
| Prospective Studies | 9 | 2020 | 6475 | 0.420 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 140 | 0.410 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 48 | 0.400 |
Why?
|
| Cohort Studies | 7 | 2024 | 5085 | 0.390 |
Why?
|
| Receptors, Prolactin | 2 | 2013 | 11 | 0.380 |
Why?
|
| Cell Proliferation | 1 | 2020 | 2468 | 0.380 |
Why?
|
| Anemia | 5 | 2002 | 354 | 0.380 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 731 | 0.350 |
Why?
|
| Pregnancy Reduction, Multifetal | 1 | 2011 | 18 | 0.350 |
Why?
|
| Ovarian Cysts | 1 | 2011 | 23 | 0.350 |
Why?
|
| Retrospective Studies | 13 | 2025 | 17653 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 5 | 2025 | 4701 | 0.320 |
Why?
|
| Infertility | 2 | 2008 | 73 | 0.310 |
Why?
|
| Mice | 8 | 2025 | 18224 | 0.290 |
Why?
|
| Vitrification | 2 | 2019 | 5 | 0.290 |
Why?
|
| Metrorrhagia | 1 | 2008 | 8 | 0.290 |
Why?
|
| Peritoneum | 1 | 2008 | 36 | 0.280 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 452 | 0.270 |
Why?
|
| Pregnancy, Ectopic | 2 | 2024 | 20 | 0.270 |
Why?
|
| Biomarkers | 2 | 2015 | 3397 | 0.260 |
Why?
|
| Sensitivity and Specificity | 4 | 2021 | 2121 | 0.260 |
Why?
|
| Chorionic Gonadotropin | 1 | 2007 | 78 | 0.250 |
Why?
|
| Ovulation | 1 | 2007 | 105 | 0.250 |
Why?
|
| Young Adult | 6 | 2025 | 9991 | 0.240 |
Why?
|
| Fetal Diseases | 4 | 2002 | 458 | 0.240 |
Why?
|
| Terminology as Topic | 2 | 2024 | 226 | 0.240 |
Why?
|
| Semen Preservation | 1 | 2025 | 16 | 0.230 |
Why?
|
| Organ Size | 2 | 2020 | 424 | 0.230 |
Why?
|
| Fertility | 2 | 2021 | 258 | 0.230 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 93 | 0.230 |
Why?
|
| HELLP Syndrome | 1 | 2005 | 13 | 0.230 |
Why?
|
| Bone Morphogenetic Protein 15 | 1 | 2025 | 44 | 0.230 |
Why?
|
| Receptors, Androgen | 1 | 2008 | 414 | 0.220 |
Why?
|
| Growth Differentiation Factor 9 | 1 | 2025 | 50 | 0.220 |
Why?
|
| Animals | 8 | 2025 | 33899 | 0.220 |
Why?
|
| Puerperal Disorders | 1 | 2005 | 45 | 0.220 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2005 | 66 | 0.220 |
Why?
|
| Blood Transfusion, Intrauterine | 2 | 2002 | 37 | 0.220 |
Why?
|
| Fibroblasts | 1 | 2008 | 856 | 0.210 |
Why?
|
| Fetal Blood | 4 | 2020 | 177 | 0.210 |
Why?
|
| Mesenteric Artery, Superior | 2 | 2001 | 33 | 0.210 |
Why?
|
| Heparin | 1 | 2005 | 204 | 0.200 |
Why?
|
| Aminopyridines | 1 | 2024 | 63 | 0.200 |
Why?
|
| Spermatozoa | 1 | 2025 | 254 | 0.200 |
Why?
|
| Gestational Age | 11 | 2005 | 1228 | 0.200 |
Why?
|
| Pregnancy Proteins | 1 | 2023 | 13 | 0.190 |
Why?
|
| Reference Values | 3 | 2019 | 680 | 0.190 |
Why?
|
| Karyopherins | 1 | 2023 | 36 | 0.190 |
Why?
|
| Pyrroles | 1 | 2024 | 184 | 0.190 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2001 | 57 | 0.180 |
Why?
|
| Cancer Survivors | 1 | 2025 | 268 | 0.180 |
Why?
|
| Ki-67 Antigen | 1 | 2021 | 106 | 0.170 |
Why?
|
| Endometriosis | 1 | 2024 | 176 | 0.170 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2001 | 97 | 0.170 |
Why?
|
| Peritoneal Cavity | 1 | 2020 | 20 | 0.170 |
Why?
|
| Body Mass Index | 1 | 2007 | 1684 | 0.170 |
Why?
|
| Fetal Growth Retardation | 4 | 2006 | 254 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 172 | 0.170 |
Why?
|
| Suction | 1 | 2020 | 50 | 0.160 |
Why?
|
| Oocyte Retrieval | 1 | 2020 | 5 | 0.160 |
Why?
|
| Follicular Fluid | 1 | 2020 | 6 | 0.160 |
Why?
|
| Pressure | 1 | 2020 | 122 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 3816 | 0.160 |
Why?
|
| Adolescent | 4 | 2025 | 20774 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2005 | 597 | 0.160 |
Why?
|
| Caspase 3 | 1 | 2020 | 127 | 0.160 |
Why?
|
| Nomograms | 1 | 2019 | 37 | 0.150 |
Why?
|
| Mice, Nude | 1 | 2020 | 705 | 0.150 |
Why?
|
| Analysis of Variance | 1 | 2020 | 944 | 0.140 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2018 | 39 | 0.140 |
Why?
|
| Hot Temperature | 1 | 2019 | 141 | 0.140 |
Why?
|
| Nanog Homeobox Protein | 1 | 2018 | 28 | 0.140 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2018 | 55 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2025 | 901 | 0.140 |
Why?
|
| Counseling | 1 | 2020 | 237 | 0.140 |
Why?
|
| Ovariectomy | 1 | 2018 | 159 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 21 | 0.140 |
Why?
|
| Receptors, LH | 1 | 2017 | 15 | 0.140 |
Why?
|
| Vaccination | 1 | 2023 | 1033 | 0.130 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 258 | 0.130 |
Why?
|
| Clomiphene | 1 | 2017 | 15 | 0.130 |
Why?
|
| Premenopause | 1 | 2017 | 38 | 0.130 |
Why?
|
| Risk Factors | 4 | 2015 | 10993 | 0.130 |
Why?
|
| Genitalia, Female | 1 | 2017 | 46 | 0.120 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2001 | 427 | 0.120 |
Why?
|
| Biopsy | 2 | 2011 | 1238 | 0.120 |
Why?
|
| Blood Glucose | 1 | 2020 | 1107 | 0.110 |
Why?
|
| Glucose Intolerance | 1 | 2015 | 80 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2020 | 552 | 0.110 |
Why?
|
| ROC Curve | 2 | 2015 | 616 | 0.110 |
Why?
|
| Insulin Resistance | 1 | 2020 | 683 | 0.110 |
Why?
|
| Prognosis | 3 | 2020 | 4927 | 0.110 |
Why?
|
| Regional Blood Flow | 2 | 2006 | 194 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 988 | 0.100 |
Why?
|
| Bone Development | 1 | 2014 | 57 | 0.100 |
Why?
|
| Receptors, Thyrotropin | 1 | 2013 | 8 | 0.100 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 119 | 0.100 |
Why?
|
| Puberty | 1 | 2014 | 94 | 0.100 |
Why?
|
| Incidence | 1 | 2021 | 3344 | 0.100 |
Why?
|
| Prolactin | 1 | 2013 | 112 | 0.100 |
Why?
|
| Fetofetal Transfusion | 3 | 2001 | 206 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2014 | 237 | 0.100 |
Why?
|
| Sexual Development | 1 | 2013 | 24 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 3053 | 0.100 |
Why?
|
| Testosterone | 1 | 2018 | 590 | 0.100 |
Why?
|
| Femur | 1 | 2013 | 78 | 0.090 |
Why?
|
| Hormones | 1 | 2013 | 162 | 0.090 |
Why?
|
| Middle Aged | 4 | 2025 | 28448 | 0.090 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 261 | 0.090 |
Why?
|
| Triplets | 1 | 2011 | 9 | 0.090 |
Why?
|
| Luteal Cells | 1 | 2011 | 7 | 0.090 |
Why?
|
| Organ Preservation | 1 | 2012 | 60 | 0.090 |
Why?
|
| Oocyte Donation | 1 | 2011 | 4 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 2 | 2002 | 20 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 326 | 0.080 |
Why?
|
| Estrogen Receptor beta | 1 | 2011 | 76 | 0.080 |
Why?
|
| Amniotic Fluid | 3 | 2001 | 149 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2024 | 793 | 0.080 |
Why?
|
| Systole | 4 | 2002 | 196 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1622 | 0.070 |
Why?
|
| Fertility Agents | 1 | 2008 | 1 | 0.070 |
Why?
|
| Gene Expression | 1 | 2013 | 1489 | 0.070 |
Why?
|
| Body Weight | 1 | 2013 | 988 | 0.070 |
Why?
|
| Peritoneal Diseases | 1 | 2008 | 10 | 0.070 |
Why?
|
| Tissue Adhesions | 1 | 2008 | 27 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1214 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2014 | 12891 | 0.070 |
Why?
|
| Mycoplasma Infections | 1 | 2008 | 10 | 0.070 |
Why?
|
| Ureaplasma Infections | 1 | 2008 | 9 | 0.070 |
Why?
|
| Rubella | 1 | 2008 | 18 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2008 | 241 | 0.070 |
Why?
|
| Gonorrhea | 1 | 2008 | 43 | 0.070 |
Why?
|
| Chlamydia Infections | 1 | 2008 | 53 | 0.070 |
Why?
|
| Postmenopause | 1 | 2008 | 148 | 0.070 |
Why?
|
| Gonadotropins | 1 | 2007 | 30 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2011 | 432 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2012 | 1221 | 0.070 |
Why?
|
| Cell Size | 1 | 2007 | 79 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 143 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2024 | 4665 | 0.060 |
Why?
|
| Cell Count | 1 | 2007 | 214 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2008 | 439 | 0.060 |
Why?
|
| Age Factors | 1 | 2013 | 2844 | 0.060 |
Why?
|
| Sperm Banks | 1 | 2025 | 8 | 0.060 |
Why?
|
| Placentation | 1 | 2006 | 58 | 0.060 |
Why?
|
| Maternal Age | 1 | 2005 | 134 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2005 | 350 | 0.050 |
Why?
|
| Recurrence | 1 | 2008 | 1479 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 567 | 0.050 |
Why?
|
| Umbilical Veins | 1 | 2004 | 63 | 0.050 |
Why?
|
| Male | 5 | 2025 | 64557 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2006 | 221 | 0.050 |
Why?
|
| Hematocrit | 1 | 2004 | 105 | 0.050 |
Why?
|
| Live Birth | 1 | 2023 | 64 | 0.050 |
Why?
|
| Vena Cava, Inferior | 1 | 2004 | 95 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2024 | 151 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2013 | 3712 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2005 | 204 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 266 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2004 | 192 | 0.050 |
Why?
|
| Parvovirus B19, Human | 1 | 2002 | 26 | 0.050 |
Why?
|
| Parvoviridae Infections | 1 | 2002 | 34 | 0.050 |
Why?
|
| Ribosomal Proteins | 1 | 2023 | 71 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2903 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2023 | 118 | 0.050 |
Why?
|
| Fetal Hemoglobin | 1 | 2002 | 27 | 0.050 |
Why?
|
| Child | 2 | 2013 | 26145 | 0.050 |
Why?
|
| Rh Isoimmunization | 2 | 2000 | 27 | 0.050 |
Why?
|
| Retreatment | 1 | 2001 | 86 | 0.040 |
Why?
|
| Cell Survival | 1 | 2024 | 840 | 0.040 |
Why?
|
| Cerebral Arteries | 1 | 2002 | 80 | 0.040 |
Why?
|
| Pulmonary Circulation | 1 | 2002 | 114 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2011 | 8553 | 0.040 |
Why?
|
| Embryonic Development | 1 | 2023 | 204 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2306 | 0.040 |
Why?
|
| Diseases in Twins | 1 | 2000 | 88 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 369 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2002 | 822 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 199 | 0.040 |
Why?
|
| Hemorheology | 1 | 1998 | 25 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 1486 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2002 | 442 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 1998 | 52 | 0.030 |
Why?
|
| Pregnancy in Diabetics | 1 | 1997 | 15 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2002 | 489 | 0.030 |
Why?
|
| Liver | 1 | 2004 | 1802 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 1997 | 233 | 0.030 |
Why?
|
| Insulin | 1 | 2020 | 1146 | 0.030 |
Why?
|
| Time Factors | 2 | 2001 | 6223 | 0.030 |
Why?
|
| Blood Pressure | 1 | 1998 | 1342 | 0.020 |
Why?
|
| Cordocentesis | 2 | 2002 | 11 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2002 | 287 | 0.020 |
Why?
|
| Drainage | 2 | 2001 | 249 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1997 | 875 | 0.020 |
Why?
|
| Amniocentesis | 2 | 1998 | 77 | 0.020 |
Why?
|
| Ureaplasma urealyticum | 1 | 2008 | 2 | 0.020 |
Why?
|
| Mycoplasma hominis | 1 | 2008 | 3 | 0.020 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2008 | 15 | 0.020 |
Why?
|
| Chlamydia trachomatis | 1 | 2008 | 29 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2002 | 2932 | 0.010 |
Why?
|
| Hydrops Fetalis | 1 | 2002 | 85 | 0.010 |
Why?
|
| Pregnancy, High-Risk | 1 | 2002 | 38 | 0.010 |
Why?
|
| Amnion | 1 | 2001 | 41 | 0.010 |
Why?
|
| Medical Records | 1 | 2002 | 181 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 2683 | 0.010 |
Why?
|
| International Cooperation | 1 | 2001 | 156 | 0.010 |
Why?
|
| Encephalomalacia | 1 | 2000 | 4 | 0.010 |
Why?
|
| Morbidity | 1 | 2001 | 260 | 0.010 |
Why?
|
| Blood Group Incompatibility | 1 | 2000 | 27 | 0.010 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2000 | 30 | 0.010 |
Why?
|
| Fetal Death | 1 | 2000 | 120 | 0.010 |
Why?
|
| Isoantibodies | 1 | 2000 | 62 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2000 | 189 | 0.010 |
Why?
|
| Cerebral Palsy | 1 | 2000 | 86 | 0.010 |
Why?
|
| Pregnancy Trimesters | 1 | 1998 | 34 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1998 | 124 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1998 | 167 | 0.010 |
Why?
|
| Diastole | 1 | 1998 | 178 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2001 | 1509 | 0.010 |
Why?
|
| Hexosamines | 1 | 1997 | 17 | 0.010 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1998 | 92 | 0.010 |
Why?
|
| Birth Weight | 1 | 1998 | 343 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1998 | 315 | 0.010 |
Why?
|
| Registries | 1 | 2001 | 1594 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2000 | 1907 | 0.000 |
Why?
|